Diazoxide

CARDIOVASCULAR SYSTEM

Key facts

Diazoxide is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1973. DrugCentral lists 3 molecular targets, including ABCC8|KCNJ11, Kcnj11 and NAMPT. Recorded indications include Hyperinsulinism, Hypertensive Emergencies, Hypertensive urgency and Insulinoma.

• Approval status: ofp (first approved 1973 by the FDA).
• Molecular targets: ABCC8|KCNJ11, Kcnj11 and NAMPT (3 listed in DrugCentral).
• Indications: Hyperinsulinism, Hypertensive Emergencies, Hypertensive urgency, Insulinoma and Islet cell hyperplasia.
• ATC code: C02DA01 (Thiazide derivatives).
• Molecular formula: C8H7ClN2O2S; molecular weight 230.67 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Hyperinsulinism
• Hypertensive Emergencies
• Hypertensive urgency
• Insulinoma
• Islet cell hyperplasia

Off-label uses (1)

• Hypertensive Emergency associated with Pregnancy

Contraindications (19)

• Body fluid retention
• Cerebrovascular disease
• Chronic heart failure
• Chronic myocardial ischemia
• Decreased cardiac function
• Diabetes mellitus
• Disease of liver
• Edema
• Gout
• Hyperglycemia
• Hyperkalemia
• Hypertension due to Aortic Coarctation
• Hypertension due to Arteriovenous Shunt
• Hyperuricemia
• Hypokalemia
• Ketoacidosis
• Kidney disease
• Orthostatic hypotension
• Uremia

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Sulfonylurea receptor 1, Kir6.2	ABCC8|KCNJ11	opener	EC50 4.63
ATP-sensitive inward rectifier potassium channel 11	Kcnj11	activator	EC50 4.20
Nicotinamide phosphoribosyltransferase	NAMPT	unknown	Kd 3.64

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1973-01-22	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C02DA01	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON › Thiazide derivatives
V03AH01	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Drugs for treatment of hypoglycemia

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hypoglycaemia	206.9
Necrotising colitis	111.2
Insulinoma	107.5
Drug ineffective	103.9
Hyperglycaemia	100.7
Drug ineffective for unapproved indication	87.4
Hypertrichosis	68.1
Hyperglycaemic hyperosmolar nonketotic syndrome	63.2
Pulmonary hypertension	50.1
Pancreatectomy	44.7
Hypoglycaemic seizure	37.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Diazoxide is on its molecule page.

• Molecular formula: C₈H₇ClN₂O₂S
• Molecular weight: 230.67 g/mol
• CAS number: 364-98-7
• InChIKey: GDLBFKVLRPITMI-UHFFFAOYSA-N
• PubChem CID: 3019

CC1=NC2=CC=C(Cl)C=C2S(=O)(=O)N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Diazoxide used for?

DrugCentral lists the following indications for Diazoxide: Hyperinsulinism, Hypertensive Emergencies, Hypertensive urgency, Insulinoma and Islet cell hyperplasia.

How does Diazoxide work?

Its molecular targets in DrugCentral include ABCC8|KCNJ11 (opener), Kcnj11 (activator) and NAMPT.

When was Diazoxide first approved?

Diazoxide was first approved by the FDA in 1973.

What is the chemical formula of Diazoxide?

Diazoxide has the molecular formula C8H7ClN2O2S and a molecular weight of 230.67 g/mol.

Sources

• DrugCentral drug card 854 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL181 — compound record and bioactivity
• PubChem CID 3019 — chemical identifiers
• DrugBank DB01119 — drug record
• FDA UNII O5CB12L4FN — substance identity
• DailyMed: FDA labels for Diazoxide — current prescribing information (label search)
• UniProt P43490 (NAMPT) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.